Sevelamer Carbonate Tablet
Product Images NDC 72789-562

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Sevelamer Carbonate (NDC 72789-562). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

72789562 Label (72789562)

Label for Sevelamer Carbonate 800 mg film-coated tablets by PD-Rx Pharmaceuticals, Inc., marketed in a 270-count prescription bottle. The label includes storage instructions, manufacturer details, barcode, and expiration date. The product is identified with NDC 72789-562-94 and manufactured for AiPing Pharmaceutical, Inc.*

FDA Label Image

Figure-1 (Fig 1)

Chemical structure diagram of sevelamer carbonate, showing its polymeric form with ammonium, bicarbonate, amine, and hydroxyl groups as part of the repeating molecular units.*

FDA Label Image

Figure-2 (Fig 2)

A forest plot chart showing subgroup analyses comparing Sevelamer Carbonate versus placebo. The subgroups include Overall, Screening BSA (<1.2, >=1.2 m2), Baseline Serum Phosphorus (<7, >=7 mg/dL), Age (<13, >=13 years), and On Dialysis (Yes, No). The chart displays LSM mean differences with 95% confidence intervals for N=97 participants, visually representing effect sizes favoring Sevelamer Carbonate or placebo.*

FDA Label Image

Figure-3 (Fig 3)

A line graph showing the percentage of patients with a reduction in serum phosphorus (mg/dL) on the x-axis and the percentage of patients with reduction greater than x on the y-axis. The graph compares Sevelamer Hydrochloride and an Active Control, illustrating changes from baseline in serum phosphorus levels, with annotations indicating worsened increase and improved reduction ranges.*

FDA Label Image

Figure-4 (Fig 4)

A line graph showing phosphorus change from baseline over 52 study weeks, comparing treatments Sevelamer Hydrochloride and Active-Control. The x-axis represents study weeks, and the y-axis indicates phosphorus level change, with both treatments demonstrating a similar trend of decreasing phosphorus levels from baseline.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.